After being voluntarily withdrawn 7 years ago, gemtuzumab ozogamicin (Mylotarg) is now returning to the market for the treatment of acute myeloid leukemia.FDA Approvals

Related Links:

Condition:   Acute Myeloid Leukemia Interventions:   Drug: Azacitidine;   Drug: Cladribine;   Drug: Cytarabine;   Drug: Venetoclax Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting

The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions.   It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell lung cancer, and multiple myeloma.  In neuroblastoma, patients undergo a very aggress ive standard of care regimen that results in a high mortality rate.  Many neuroblastomas have increased expression of CD56, which represents a possible therapeutic target for these…

Charlotte Jenkins, 16, from Stockport in Greater Manchester battled against a rare form of acute myeloid leukaemia to be able to sit her GCSEs and go to her end of school prom.

Researchers have identified genetic mutations that may occur years before acute myeloid leukemia actually develops, giving new clues as to how the disease begins.Medscape Medical News

Charlotte Jenkins, 16, from Stockport in Greater Manchester battled against a rare form of acute myeloid leukaemia to be able to sit her GCSEs and go to her end of school prom.

Publication date: Available online 30 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Alan K. BurnettAbstractOlder patients with acute myeloid leukemia represent at least one half of those with the disease for whom randomized clinical trials of new treatments are in development. These patients represent an appropriate population in which to evaluate new treatments against the current standards of care, which could be azacitidine, decitabine, or low-dose cytarabine. However, despite the identification of treatments that can deliver a worthwhile increase in remission, none has yet delivered a survival super…

Roche today announced submission of a supplemental New Drug Application (sNDA) to the United States (U.S.) Food and Drug Administration (FDA) for Venclexta  (venetoclax), in combination with a hypomethylating agent or in combination with low dose cytarabine (LDAC), for treatment of people with previously untreated acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.

Mutations in receptor tyrosine kinase/RAS signaling pathway genes are frequent in core-binding factor (CBF) acute myeloid leukemias (AMLs), but their prognostic relevance is debated. A subset of CBF AML patients harbors several signaling gene mutations. Genotyping of colonies and of relapse samples indicates that these arise in independent clones, thus defining a process of clonal interference (or parallel evolution). Clonal interference is pervasive in cancers, but the mechanisms underlying this process remain unclear, and its prognostic impact remains unknown. We analyzed a cohort of 445 adult and pediatric patients with…

Source: BloodCategory: Hematology Authors: Tags: Myeloid Neoplasia Source Type: research

Authors: Zhao Y, Zhong L, Liu L, Yao SF, Chen M, Li LW, Shan ZL, Xiao CL, Gan LG, Xu T, Liu BZ
Abstract
At present, acute promyelocytic leukemia (APL) is the most curable form of acute myeloid leukemia and can be treated using all-trans retinoic acid and arsenic trioxide. However, the current treatment of APL is associated with some issues such as drug toxicity, resistance and relapse. Therefore, other strategies are necessary for APL treatment. In the present study, we investigated the effects of salinomycin (SAL) on APL cell lines NB4 and HL-60 and determined its possible mechanisms. We observed that SAL inhibite…

Source: Oncology ReportsCategory: Cancer & Oncology Tags: Oncol Rep Source Type: research

Conclusion: Together with changes in the expression/function of receptors targeted by TKIs, the expression of plasma membrane transporters involved in sorafenib uptake/efflux may affect the response of leukemia cells to this drug.
PMID: 29983874 [PubMed]

Source: OncotargetCategory: Cancer & Oncology Tags: Oncotarget Source Type: research





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here